Evidence map›Paper›PMID 34345408›Full record

ReviewClinical kidney journal2021

Assessment of kidney function: clinical indications for measured GFR.

Natalie Ebert, Sebastjan Bevc, Arend Bökenkamp, Francois Gaillard, Mads Hornum, Kitty J Jager, Christophe Mariat, Bjørn Odvar Eriksen, Runolfur Palsson, Andrew D Rule and 3 more

Open access · goldAbstract readReview
In one paragraph

Review in Clinical kidney journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Indexing for body surface area when assessing kidney function.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Observational
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 12 institutions in 9 countries.

Natalie EbertInstitute of Public Health, Charité Universitätsmedizin Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-4463-3315
Sebastjan BevcDepartment of Nephrology, Faculty of Medicine, Clinic for Internal Medicine, University Medical Center Maribor, University of Maribor, Maribor, Slovenia.
Arend BökenkampDepartment of Pediatric Nephrology, Amsterdam University Medical Center, Emma Kinderziekenhuis, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-3492-2252
Francois GaillardAP-HP, Hôpital Bichat, Service de Néphrologie, Université de Paris, INSERM U1149, Paris, France.ORCID https://orcid.org/0000-0002-7248-8418
Mads HornumDepartment of Nephrology, Rigshospitalet and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Kitty J JagerDepartment of Medical Informatics, ERA-EDTA Registry, Amsterdam Public Health Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Christophe MariatHôpital Nord, CHU de Saint-Etienne, Saint-Etienne, France.
Bjørn Odvar EriksenMetabolic and Renal Research Group, UiT The Arctic University of Norway, Tromsø, Norway.
Runolfur PalssonInternal Medicine Services, Division of Nephrology, Landspitali-The National University Hospital of Iceland and Faculty of Medicine, University of Iceland, Reykjavik, Iceland.ORCID https://orcid.org/0000-0001-6763-1702
Andrew D RuleDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Marco van LondenDepartment of Internal Medicine, Division of Nephrology, University Medical Center Groningen, Groningen, The Netherlands.
Christine WhiteDepartment of Medicine, Division of Nephrology, Queen's University, Kingston, Canada.
Elke SchaeffnerInstitute of Public Health, Charité Universitätsmedizin Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin · DEAmsterdam University Medical Centers · NLEmma Kinderziekenhuis · NLHôpital Nord · FRInserm · FRMayo Clinic · USQueen's University · CAUiT The Arctic University of Norway · NOUniversity Medical Center Groningen · NLUniversity of Copenhagen · DKUniversity of Iceland · ISUniversity of Maribor · SI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the vast majority of cases, glomerular filtration rate (GFR) is estimated using serum creatinine, which is highly influenced by age, sex, muscle mass, body composition, severe chronic illness and many other factors. This often leads to misclassification of patients or potentially puts patients at risk for inappropriate clinical decisions. Possible solutions are the use of cystatin C as an alternative endogenous marker or performing direct measurement of GFR using an exogenous marker such as iohexol. The purpose of this review is to highlight clinical scenarios and conditions such as extreme body composition, Black race, disagreement between creatinine- and cystatin C-based estimated GFR (eGFR), drug dosing, liver cirrhosis, advanced chronic kidney disease and the transition to kidney replacement therapy, non-kidney solid organ transplant recipients and living kidney donors where creatinine-based GFR estimation may be invalid. In contrast to the majority of literature on measured GFR (mGFR), this review does not include aspects of mGFR for research or public health settings but aims to reach practicing clinicians and raise their understanding of the substantial limitations of creatinine. While including cystatin C as a renal biomarker in GFR estimating equations has been shown to increase the accuracy of the GFR estimate, there are also limitations to eGFR based on cystatin C alone or the combination of creatinine and cystatin C in the clinical scenarios described above that can be overcome by measuring GFR with an exogenous marker. We acknowledge that mGFR is not readily available in many centres but hope that this review will highlight and promote the expansion of kidney function diagnostics using standardized mGFR procedures as an important milestone towards more accurate and personalized medicine.

Indexed as

biomarkerchronic kidney diseaseclinical indicationscreatininecystatin Ckidney functionmeasured glomerular filtration rate

Identifiers

PMID34345408
PMCPMC8323140
OpenAlexW3132093483

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.